With the advent of modern medicine and its contribution to the dramatic increase in human lifespan,
cancer and neurological diseases have become some of the leading causes of mortality and morbidity globally. Diagnosing these diseases earlier can grant the patient a chance to increase one’s health and life span with better controlled symptoms, while allowing for families to prepare for the difficulties ahead.
Therefore, detecting both cancer and neurological disorders early has become both a challenge and an objective for the medical community.
A team of Stanford University physicians,
UC Berkeley PhD’s, and the 2013 Nobel Laureatechemist
gathered together to develop a sensitive and specific breath diagnostic for cancer and neurological diseases. This diagnostic aims to collect Volatile Organic Compounds(VOCs), which are compounds with high vapor pressure or volatility at room temperature, carried from the body to the lungs as products of endogenous biochemical processes.
*Note: For complete description of therapeutics and diagnostics with citations, please refer to ABC ICO Prospectus
The breath diagnostic system is designed to detect signature patterns in VOC’s collected from patients to ascertain the presence of a multitude of cancers and neurodegenerative diseases, based on the clinical evidence that distinctive breath signatures could be indicative of various clinical conditions such as diabetes, liver failure, chronic renal disease, and certain inborn errors of metabolism such as cancer and neurological diseases.
Using a noninvasive and easy-to-collect sampling device, this diagnostic will first target colon cancer, prostate cancer, and multiple sclerosis on ABC’s Treatment Access Platform.